Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Financial Info
: Financials

Financials

v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 16,448 $ 25,034
Prepaid expenses and other 2,734 1,022
Total current assets 19,182 26,056
Property and equipment, net 41 43
Operating lease right-of-use assets 579  
Restricted cash 100 100
Intangible asset 120 120
Total assets 20,022 26,319
Current liabilities:    
Accounts payable 1,133 1,404
Accrued expenses and other current liabilities 498 1,251
Operating lease liabilities, current 380  
Total current liabilities 2,011 2,655
Operating lease liabilities, noncurrent 200  
Total liabilities 2,211 2,655
Commitments (See Note 9)
Stockholders' equity:    
Preferred stock, 5,000,000 shares authorized Series A Convertible Preferred stock, $0.001 par value; 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively  
Common stock, $0.001 par value; 15,000,000 shares authorized; 6,089,728 and 3,251,970 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively, and 1,758 shares to be issued as of December 31, 2018 6 3
Additional paid in capital 212,529 212,154
Accumulated deficit (194,685) (188,452)
Accumulated other comprehensive loss (39) (41)
Total stockholders' equity 17,811 23,664
Total liabilities and stockholders' equity $ 20,022 $ 26,319
v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
COSTS AND EXPENSES:    
Research and development $ 3,896 $ 5,170
General and administrative 2,401 1,818
Total costs and expenses 6,297 6,988
Operating loss (6,297) (6,988)
Interest income, net 64 53
Net loss $ (6,233) $ (6,935)
Net loss per common share, basic and diluted (in dollars per share) $ (1.29) $ (8.80)
Weighted average common shares outstanding, basic and diluted (in shares) 4,848,199 787,900
v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (6,233) $ (6,935)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 9 15
Stock-based compensation 305 399
Changes in operating assets and liabilities:    
Prepaid expenses and other (1,700) (481)
Accounts payable (270) (32)
Accrued expenses and deferred rent (750) 263
Net cash used in operating activities (8,639) (6,771)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (7) (2)
Net cash used by investing activities (7) (2)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the exercise of warrants 70
Proceeds, net of expenses of $45, from sale of common stock 532
Net cash provided by financing activities 70 532
Effect of currency rate change on cash (10) (2)
Net decrease in cash, cash equivalents and restricted cash (8,586) (6,243)
Cash, cash equivalents and restricted cash beginning of the period 25,134 25,585
Cash, cash equivalents and restricted cash end of period 16,548 $ 19,342
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 3